 |
Phytopharm and Unilever Enter into a Licence
and Joint Development Agreement for Hoodia Gordonii Extract.
Cont.
NOTES TO EDITORS :
Unilever is one of the world's largest consumer products companies
with annual sales of $48.4 billion in 2003. It produces and markets
a wide range of foods and home and personal care products including
Becel, Bertolli, Birds Eye, Blue Band, Country Crock, Findus, Flora
Pro-Activ, Heart, Hellmann's, Iglo, Knorr, Lipton, Rama, and
SlimFast. Unilever operates in more than 100 countries around the
globe and employs approximately 230,000 people.
The CSIR is the largest public Research and Development organisation
in Africa. It has a turnover of US$150 million and a staff
complement of approximately 2500 specialist scientists, engineers,
technologists and support staff who undertake broadly-based,
market-driven research and development for the benefit of the
commercial market place, as
well as urban and rural communities in South Africa and the region.
In 2003, the CSIR entered a benefit sharing agreement with the South
African San Council, who represent the peoples whose traditional use
led to the investigation of the Hoodia plant.
Phytopharm is focused on the research and development of novel
pharmaceutical and functional food products based on clinical and
pre-clinical data generated from medicinal plant extracts. The
Company has seven development programmes in four disease areas:
neurodegeneration, obesity and metabolic disease, dermatology and
inflammation and has a portfolio of two marketed veterinary
products.
More information concerning Phytopharm's activities can be found on
its web site at
www.phytopharm.com.
This press release may contain forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933 and
Section
21E of the U.S. Securities Exchange Act of 1934 with respect to the
financial condition, results and business achievements / performance
of Phytopharm and certain of the plans and objectives of its
management.
These statements are statements that are not historical facts. Words
such as "should," "expects," "anticipates," "estimates," "believes"
or similar expressions, as they relate to Phytopharm, are intended
to identify forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they
reflect Phytopharm's current expectations and assumptions as to
future events and circumstances that may not prove accurate. There
is no guarantee that the expected events, trends or results will
actually occur. Any changes in such assumptions or expectations
could cause actual results to differ materially from current
expectations.
|
 |
